• No results found

Aberrant histone modification in CD19<sup>+</sup> B cells of the patients with chronic lymphocytic leukemia

N/A
N/A
Protected

Academic year: 2020

Share "Aberrant histone modification in CD19<sup>+</sup> B cells of the patients with chronic lymphocytic leukemia"

Copied!
7
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Primer sequences
Table 2 Demographic and clinical characteristics of patients with cll (n=58)
Figure 1 Global histone H3/H4 acetylation and H3K9 methylation in subjects.Notes: The global histone H3/H4 hypoacetylation in the CD19+ B cells of patients with cll compared with controls (A and B) (P=0.028 and P=0.03, respectively)
Figure 3 The eZh2 mrna expression in subjects.Notes: The expression level of EZH2 mRNA in patients with CLL was significantly higher than that of healthy controls (P=0.02) (A)
+2

References

Related documents

EXISTENCE RESULTS FOR ? LAPLACIAN BOUNDARY VALUE PROBLEMS ON TIME SCALES ALBERTO CABADA Received 24 January 2006; Revised 31 May 2006; Accepted 1 June 2006 This paper is devoted to

Deep Sequencing of RNA from Blood and Oral Swab Samples Reveals the Presence of Nucleic Acid from a Number of Pathogens in Patients with Acute Ebola Virus Disease and Is Consistent

The prevalence of anxiety, somatization disorder, alcohol abuse and eating disorders was greater in Guasca than Guatavita with a prevalence of 32.5% and 25.7% for an- xiety, 73.8%

It is recommended that locally available technology of biomass harnessing and processing such as briquetting as well as clean energy subsidies should be promoted

The model will demonstrate the effects of pre-colonial African customary laws and colonially-imposed laws on the creation and exacerbation of queer- phobic societal sentiment

No physician, dentist, or veterinarian shall administer, dispense, give away, deliver or prescribe any of said drugs except after a physical examination of the

by the cloud [3]. AnonyControl is a semianonymous privilege control scheme to address not only the data privacy, but also the user identity. privacy in existing

Secondary outcomes include culture-proven bacteraemia at 12 and 24 months; primary, secondary and functional patency rates at 3, 6, 12 and 24 months; stenosis, thrombosis